Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 9OTHER 8FED 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 3Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

enzalutamide 3apalutamide 2relugolix 1pembrolizumab 1nilutamide 1histrelin 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abiraterone 1Triptorelin Pamoate 1Prednisone 1Oxaliplatin 1Methylprednisolone 1Leuprolide 1Goserelin 1Flutamide 1Fecal Microbiota Transplantation 1Docetaxel 1Androgen Antagonists 1Abiraterone Acetate 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
FED × Neoplasm Metastasis × enzalutamide × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04116775 2022-06-23

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Portland VA Medical Center

Phase 2 Unknown
32 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡